Company news

Corcept Therapeutics Incorporated news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

William Guyer to join Corcept as Chief Development Officer

August 11, 2021

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

July 28, 2021

Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

July 21, 2021

Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer

July 11, 2021

Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

June 21, 2021

Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical

June 14, 2021

Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors

June 9, 2021

Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results

May 5, 2021

Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH)

May 5, 2021

Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer

May 5, 2021

Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess

March 14, 2021

Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer

February 28, 2021

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results

February 22, 2021

Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update

February 7, 2021

Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call

January 31, 2021

Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Directors

November 22, 2020

U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcept’s U.S. Patent No.10,195,214

November 17, 2020

Corcept Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update

November 2, 2020

Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic Medication

September 9, 2020

Corcept Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

August 3, 2020

Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing’s Syndrome of Adrenal Origin

July 27, 2020

Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer

July 22, 2020

Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

June 29, 2020

Corcept Therapeutics to Present Data at the American Association of Cancer Research Annual Meeting

June 14, 2020

Corcept Therapeutics to Present Data at the American Society of Clinical Oncology Annual Meeting

May 13, 2020

Corcept Therapeutics Announces First Quarter 2020 Financial Results And Provides Corporate Update

May 3, 2020

Corcept Therapeutics publishes abstract in the journal of the Endocrine Society

March 31, 2020

Corcept Therapeutics Appoints Gregg Alton to Board of Directors

March 11, 2020

Corcept Therapeutics Announces Fourth Quarter And Full-Year 2019 Audited Financial Results And Provides Corporate Update

February 19, 2020

Corcept Therapeutics to Announce Audited Financial Results, Provide Corporate Update and Host Conference Call

February 12, 2020

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2019 Preliminary Selected Financial Results; Provides 2020 Revenue Guidance

January 29, 2020

Corcept Therapeutics Announces Third quarter 2019 Financial Results and provides corporate update

November 6, 2019

Corcept Therapeutics Appoints Kimberly Park to Board of Directors

September 17, 2019

Corcept Therapeutics to Present Data at the 2019 American Association of Clinical Endocrinologists’ 28th Annual Congress

April 17, 2019

← Newer news releases

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 10 decks. Every deck is listed under its year.